VTv Therapeutics Company Insiders
| VTVT Stock | USD 14.18 0.65 4.38% |
VTv Therapeutics employs about 16 people. The company is managed by 11 executives with a total tenure of roughly 38 years, averaging almost 3.0 years of service per executive, having 1.45 employees per reported executive. Breaking down VTv Therapeutics' management performance can provide insight into the firm performance.
VTv Therapeutics' Insider Buying Vs Selling
50
Selling | Buying |
Latest Trades
| 2022-11-28 | John A Fry | Acquired 513 @ 33.2 | View | ||
| 2021-12-20 | Ronald O Perelman | Disposed 2175 @ 46 | View |
Monitoring VTv Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
VTv |
VTv Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with VTv Therapeutics' future performance. Based on our forecasts, it is anticipated that VTv will maintain a workforce of slightly above 50 employees by December 2024.VTv Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4148) % which means that it has lost $0.4148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6213) %, meaning that it created substantial loss on money invested by shareholders. VTv Therapeutics' management efficiency ratios could be used to measure how well VTv Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.93 in 2024. Return On Capital Employed is likely to gain to -60.72 in 2024. At this time, VTv Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 23.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 10.5 M in 2024.Common Stock Shares Outstanding is likely to drop to about 1.9 M in 2024. Net Loss is likely to drop to about (23.1 M) in 2024
VTv Therapeutics Workforce Comparison
vTv Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 515. VTv Therapeutics holds roughly 16.0 in number of employees claiming about 3% of equities under Health Care industry.
VTv Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific VTv Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on VTv Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, VTv Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 4.5 | 9 | 2 | 1,279,056 | 57,657 |
| 2022-09-01 | 10.0 | 10 | 1 | 707,589 | 2,200,000 |
| 2022-03-01 | 0.1667 | 1 | 6 | 500,000 | 249,149 |
| 2021-12-01 | 1.0 | 1 | 1 | 2,498,635 | 87,000 |
| 2020-12-01 | 0.6667 | 6 | 9 | 2,925,000 | 180,006 |
| 2020-06-01 | 3.5 | 7 | 2 | 721,250 | 2.00 |
| 2020-03-01 | 0.5714 | 4 | 7 | 3,761,667 | 11,673 |
| 2019-12-01 | 1.0 | 8 | 8 | 5,549,454 | 8.00 |
| 2019-09-01 | 0.9167 | 11 | 12 | 5,817,290 | 12.00 |
| 2019-06-01 | 1.25 | 5 | 4 | 2,615,819 | 4.00 |
| 2019-03-01 | 1.1111 | 10 | 9 | 3,797,536 | 11,674 |
| 2018-12-01 | 0.8333 | 5 | 6 | 4,574,618 | 6.00 |
| 2018-09-01 | 0.875 | 7 | 8 | 4,905,953 | 8.00 |
| 2018-06-01 | 1.5 | 6 | 4 | 1,212,802 | 4.00 |
| 2018-03-01 | 1.0 | 1 | 1 | 11,667 | 11,667 |
| 2016-03-01 | 5.0 | 15 | 3 | 163,114 | 13,044 |
| 2015-12-01 | 11.0 | 11 | 1 | 344,044 | 0.00 |
| 2015-09-01 | 2.2 | 22 | 10 | 2,507,690 | 2,688,372 |
VTv Therapeutics Notable Stakeholders
A VTv Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as VTv Therapeutics often face trade-offs trying to please all of them. VTv Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting VTv Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Paul MSc | President CEO | Profile | |
| Steven MBA | Executive CFO | Profile | |
| Richard Nelson | Executive Director | Profile | |
| David III | Sr Counsel | Profile | |
| Vanessa McDade | Chief Officer | Profile | |
| Elizabeth Keiley | Executive Counsel | Profile | |
| Carmen Valcarce | Chief VP | Profile | |
| MD FACC | Executive Chairperson | Profile | |
| Thomas MD | Chief Officer | Profile | |
| MSc MSc | Pres CEO | Profile | |
| Barry Brown | Chief Officer | Profile |
About VTv Therapeutics Management Performance
The success or failure of an entity such as vTv Therapeutics often depends on how effective the management is. VTv Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of VTv management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the VTv management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.84) | (1.93) | |
| Return On Capital Employed | (63.91) | (60.72) | |
| Return On Assets | (1.84) | (1.93) | |
| Return On Equity | 0.82 | 0.47 |
Please note, the imprecision that can be found in VTv Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of vTv Therapeutics. Check VTv Therapeutics' Beneish M Score to see the likelihood of VTv Therapeutics' management manipulating its earnings.
VTv Therapeutics Workforce Analysis
Traditionally, organizations such as VTv Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare VTv Therapeutics within its industry.VTv Therapeutics Manpower Efficiency
Return on VTv Therapeutics Manpower
| Revenue Per Employee | 562 | |
| Revenue Per Executive | 818 | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 1.8M | |
| Working Capital Per Employee | 2.4K | |
| Working Capital Per Executive | 3.5K |
Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.